Buscar

01/08/2025 Fibrosis quantification in hidradenitis suppurativa tunnels: Histological correlation with shear wave elastography
Mateu-Arrom, L, Mozos, A, Puig, L, Vilarrasa, E. Fibrosis quantification in hidradenitis suppurativa tunnels: Histological correlation with shear wave elastography. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(8)DOI:10.1111/jdv.20514. PMID:39699957. IF:8.000(Q1/1D).
22/03/2025 SSX and SS18-SSX Antibodies as Additional Tools for Diagnosing Undifferentiated Neoplasms With the EWSR1::SSX3 Fusion
Machado, I, Llombart-Bosch, A, Fumagalli, C, Antonescu, CR. SSX and SS18-SSX Antibodies as Additional Tools for Diagnosing Undifferentiated Neoplasms With the EWSR1::SSX3 Fusion. GENES CHROMOSOMES & CANCER. 2025; 64(3)DOI:10.1002/gcc.70044. PMID:40119747. IF:2.800(Q2/5D).
01/01/2023 Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E, Espinosa I, Felicioni L, Buttitta F, Prat J. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.. HUMAN PATHOLOGY. 2023; 141DOI:10.1016/j.humpath.2023.08.010. PMID:37673346. IF:2.700(Q2/4D).
01/11/2025 Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study
Sepulveda, ZV, Tous, S, Quiros, B, Pena, GP, Castro, JB, Serrahima, MP, Galiana, IL, Marí, A, Brunet, A, Bermejo, JO, Cirauqui, BC, Diez, AF, Leon, X, Sumarroca, A, Giner, M, Clavero, O, Goma, M, Pavon, MA, Alemany, L, Bernal, MO. Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2028. PMID:. IF:65.400(Q1/1D).
01/12/2023 Diagnostic Efficacy of High-Resolution Computed Tomography Densitometry for Diagnosing Otosclerosis.
Puiggrós IV, Moreno EG, Dotu CO, Agustí MQI, Díaz FL. Diagnostic Efficacy of High-Resolution Computed Tomography Densitometry for Diagnosing Otosclerosis.. OTOLOGY & NEUROTOLOGY. 2023; 44(10)DOI:10.1097/MAO.0000000000004012. PMID:37733986. IF:1.900(Q2/3D).
01/11/2023 Second esophageal neoplasms after head and neck index tumor: Incidence, risk factors and prognosis.
Pujol A, Llansana A, Pérez-Ugarte L, Sauter B, Quer M, León X. Second esophageal neoplasms after head and neck index tumor: Incidence, risk factors and prognosis.. Acta Otorrinolaringologica Espanola. 2023; 74(6)DOI:10.1016/j.otoeng.2022.10.009. PMID:37149128. IF:(Q/D).
12/01/2026 Biomarkers for Predicting Malignant Transformation of Premalignant Lesions of the Larynx: A Systematic Review
Rodrigo, JP, de Lima-Souza, RA, López, F, Stenman, G, Agaymy, A, Quer, M, Paleri, V, Leivo, I, Nadal, A, Zidar, N, Mariano, FV, Hellquist, H, Gale, N, Ferlito, A. Biomarkers for Predicting Malignant Transformation of Premalignant Lesions of the Larynx: A Systematic Review. Diagnostics. 2026; 16(2)DOI:10.3390/diagnostics16020236. PMID:41594212. IF:3.300(Q1/2D).
01/01/2026 Standardization of Sinonasal Anatomical Terminology in Spanish: An Expert Consensus
Villatoro-Sologaistoa, JC, Villatoro-Sologaisto, JC, Casasayas-Plass, M, Martel-Martin, M, Alfonso-Carrillo, C, Armengot-Carceller, M, Dominguez-Sosa, MS, Fernandez-Liesa, R, Garcia-Lliberós, A, Gil-Melcón, M, González-Compta, X, López-Alvarez, F, López-Chacón, M, Lobo-Duro, D, Mata-Castro, N, Monjas-Cánovas, I, Moreno-Luna, R, Pardo-Muñoz, L, Pinilla-Urraca, M, Santamaría-Gadea, A, Santos-Pérez, J, Valcárcel-Martin, F, Villacampa-Aubá, JM, del Cuvillo-Bernal, A, Sánchez-Gómez, S, Massegur-Solench, H, Bernal-Sprekelsen, M, Alobid, I. Standardization of Sinonasal Anatomical Terminology in Spanish: An Expert Consensus. Acta Otorrinolaringologica Espanola. 2026; 77(1)DOI:10.1016/j.otorri.2025.512275. PMID:. IF:(Q/D).
12/02/2024 Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.. HAEMATOLOGICA. 2024; 109(2)DOI:10.3324/haematol.2023.283342. PMID:37560813. IF:10.100(Q1/2D).
15/01/2024 Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
Piñana JL, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen JJ, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual MJ, Yeshurun M, Finke J, Groll AH, Shaw PJ, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R. Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.. JOURNAL OF INFECTIOUS DISEASES. 2024; 229(1)DOI:10.1093/infdis/jiad268. PMID:37440459. IF:4.500(Q1/2D).
28/11/2023 Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: a CIBMTR analysis.
Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik MM, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan EA, Daly A, Dholaria B, Diaz MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi P, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Solh MM, Solomon SR, Ulrickson ML, Ustun C, van der Poel MWM, Verdonck LF, Wagner JL, Wang TP, Wirk B, Zeidan AM, Litzow MR, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: a CIBMTR analysis.. Blood Advances. 2023; 7(22)DOI:10.1182/bloodadvances.2023011308. PMID:37792849. IF:7.400(Q1/2D).
14/11/2023 Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial.
Sierra J, Montesinos P, Thomas X, Griskevicius L, Cluzeau T, Caillot D, Legrand O, Minotti C, Luppi M, Farkas F, Bengoudifa BR, Gilotti G, Hodzic S, Rambaldi A, Venditti A. Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial.. Blood Advances. 2023; 7(21)DOI:10.1182/bloodadvances.2023009847. PMID:37581981. IF:7.400(Q1/2D).
01/11/2023 Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.
Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, Hernandez-Boluda JC, Esquirol A, Avenoso D, Tsirigotis P, Robin M, Czerw T, Helbig G, Roddie C, Lambert J, McLornan DP. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.. Transplantation And Cellular Therapy. 2023; 29(11)DOI:10.1016/j.jtct.2023.08.020. PMID:37633414. IF:3.600(Q1/3D).
02/10/2023 Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron F, Nagler A, Galimard JE, Sanz J, Versluis J, Forcade E, Chevallier P, Sirvent A, Anthias C, Kuball J, Furst S, Rambaldi A, Sierra J, von dem Borne PA, Gallego Hernanz MP, Cluzeau T, Robinson S, Raiola AM, Labussière-Wallet H, Byrne JL, Malfuson JV, Ruggeri A, Mohty M, Ciceri F. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.. BRITISH JOURNAL OF HAEMATOLOGY. 2023; 204(1)DOI:10.1111/bjh.19130. PMID:37784256. IF:5.100(Q1/2D).
01/10/2023 Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López J, Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez AP, Dourdil V, De Arriba F, González S, Pérez-de-Oteyza J, Hernández MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.. HAEMATOLOGICA. 2023; 108(10)DOI:10.3324/haematol.2022.282490. PMID:37102598. IF:10.100(Q1/2D).
26/09/2023 Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010236. PMID:37315225. IF:7.400(Q1/2D).
23/05/2023 Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault de Latour R, Esquirol A, Michel G, Chevallier P, Rubio MT, Cornelissen JJ, Michallet M, Volt F, Rivera Franco MM, Scigliuolo GM, Cappelli B, Rocha V, Gluckman E. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.. Blood Advances. 2023; 7(10)DOI:10.1182/bloodadvances.2022007941. PMID:36350759. IF:7.400(Q1/2D).
20/01/2026 Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024
Formigo, GMS, Mazorra, Z, Olexen, C, Menéndez, T, Hadi, LA, Handgretinger, R, Hernandez, AAB, El Najjar, I, Coukos, G, Sabzevari, H, Bollard, C, Couriel, D, Wald, D, Hamieh, M, Briones, J, Al Kaabi, F, Ventura-Carmenate, Y. Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024. Frontiers in Immunology. 2026; 16DOI:10.3389/fimmu.2025.1650023. PMID:41641269. IF:5.900(Q1/2D).
01/01/2026 Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe
Ammar, D, Sanges, C, Henderson, D, Schapitz, I, Hudecek, M, Luu, M, Schüssler-Lenz, M, Buchholz, C, Franz, P, Reiche, K, Köhl, U, Ifrah, N, Quesnel, B, Thermeli, M, Kersten, MJ, Locatelli, F, D'Amore, ML, Bonini, C, Casucci, M, Philippar, U, Doeswijk, R, Thielen, F, Uyl-de Groot, C, Theelen, J, Schröder, B, Kremer, A, Quaranta, M, Prosper, F, Van den Brulle, J, Grawunder, U, Donnadieu, E, Galy, A, Ferrand, C, Worel, N, Busch, D, Briones, J, Sellner, L, Kuball, J, Sureda, A, Awigena-Cook, J. Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. CYTOTHERAPY. 2026; 28(1)DOI:10.1016/j.jcyt.2025.09.007. PMID:41217312. IF:3.200(Q2/3D).
01/01/2026 HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study
Salas, MQ, Moya, TA, Pasic, I, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Garcia, II, Mussetti, A, Lavilla, E, Lopez-Marin, J, Filaferro, S, Balsalobre, P, Bento, L, Law, A, Viswabandya, A, Michelis, F, Mattsson, J, Alibhai, S, Rovira, M, Kim, DDW, Sured, A, Kumar, R. HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study. Eclinicalmedicine. 2026; 91DOI:10.1016/j.eclinm.2025.103753. PMID:41567713. IF:10.000(Q1/1D).